Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body

Executive Summary

Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.

You may also be interested in...

Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

European Parliament Signs Off Regulation To Tackle Medicine Shortages

The legislation will establish a new EU platform for monitoring and reporting medicines shortages.

Scottish Funding OK For Breast Cancer Drugs Tukysa And Enhertu

As well as recommending Seagen’s Tukysa and Daiichi Sankyo/AstraZeneca’s Enhertu, the Scottish Medicines Consortium has given the green light to Leo Pharma’s Adtralza and a new lung cancer indication for AZ’s Tagrisso. Meanwhile, Alexion has failed to make a submission to HTAs in both Scotland and England for a specific indication for Soliris.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts